Cargando…
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the developm...
Autores principales: | Shan, Hengyue, Liu, Jianping, Shen, Jiali, Dai, Jialin, Xu, Gang, Lu, Kuankuan, Han, Chao, Wang, Yaru, Xu, Xiaolong, Tong, Yilun, Xiang, Huaijiang, Ai, Zhiyuan, Zhuang, Guanglei, Hu, Junhao, Zhang, Zheng, Li, Ying, Pan, Lifeng, Tan, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075810/ https://www.ncbi.nlm.nih.gov/pubmed/33979649 http://dx.doi.org/10.1016/j.chembiol.2021.04.020 |
Ejemplares similares
-
Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
por: Li, Lingyu, et al.
Publicado: (2022) -
Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
por: Wang, Qian, et al.
Publicado: (2023) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022) -
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023)